Please log in
You must be logged in to send the contact request.
Manage stand orders
Select Option
CAMPTON Diagnostics GmbH
Fraunhoferstr. 3,
25524
Itzehoe
Germany
Germany
Submit your contact details
Provide your contact details to the exhibitor. Optionally, you may also add a personal message.
Your name, phone number, and e-mail address are subject to the submission of personal data. Messe Düsseldorf GmbH expressly points out that for a data transmission into third countries, for which no adequacy decision of the EU-commission is on hand certifying an adequate level of protection of personal data, it is not ensured that there are appropriate safeguards for the protection of personal data on hand.
An error has occurred
Please check your internet connection or try again later.
Message has been sent
Your message to the exhibitor was sent successfully.
This company is co-exhibitor of
DiagnostikNet-BB
Media files
Contact
Please log in
You must be logged in to use matchmaking
Please log in for matchmaking
Registration is required to use the networking service and a separate registration for matchmaking. Please register for Matchmaking first.
Let's get started!
Welcome to Matchmaking. Would you like to get in touch with ?
Our range of products
Product categories
- 02 Laboratory technology
- 02.01 Analyser systems / equipment
Analyser systems / equipment
- 03 Diagnostic tests
- 03.02 Immunochemistry testing, immunology testing
- 03.02.01 Immuno assay testing
Immuno assay testing
- 03 Diagnostic tests
- 03.02 Immunochemistry testing, immunology testing
- 03.02.02 Diagnostic rapid tests
Diagnostic rapid tests
- 03 Diagnostic tests
- 03.02 Immunochemistry testing, immunology testing
- 03.02.03 Diagnostic tests for cancer
Diagnostic tests for cancer
- 03 Diagnostic tests
- 03.05 Infectious immunology testing
- 03.05.02 Microbiological diagnosis, virology, equipment and systems for
Microbiological diagnosis, virology, equipment and systems for
- 03 Diagnostic tests
- 03.05 Infectious immunology testing
- 03.05.03 Other infectious immunology testing
Other infectious immunology testing
- 03 Diagnostic tests
- 03.06 Genetic testing, molecular diagnostics
- 03.06.01 DNA testing
- 03 Diagnostic tests
- 03.06 Genetic testing, molecular diagnostics
- 03.06.03 Polymerase chain reaction (PCR)
Polymerase chain reaction (PCR)
- 03 Diagnostic tests
- 03.06 Genetic testing, molecular diagnostics
- 03.06.04 Other molecular diagnostics testing
Other molecular diagnostics testing
Our products
Product category: Analyser systems / equipment
CAMPTON Reader 100
The CAMPTON Biochip Reader helps to improve patient care and treatment.
With only a few microliters of blood, our biochip reader provides a reliable and fast diagnosis for a wide range of diseases.
Advantages of the new CAMPTON Biochip Reader System
Traditional diagnostic tests usually require laboratories and excessive equipment and highly trained personnel to deliver results in slow and time-consuming processes (e.g. 1-3 days to obtain results).
Portable diagnostic devices like the CAMPTON Reader 100 overcome these limitations: The fully automated platform performs sample extraction, preparation, (amplification*) and detection within the self-contained disposable laboratory in a 'cartridge', making it easy to perform with minimal equipment and training.
The CAMPTON Reader 100 delivers rapid test results within minutes, enabling cost and time efficient diagnostics. The consolidated test design allows testing for both serological and molecular biology assays, reducing the need for multiple test platforms. Unlike competitors who often use optics to capture test results, our newly developed CAMPTON technology uses electrical signals, making the CAMPTON Reader 100 technology more robust and therefore suitable for use in almost any climate and even in the most remote locations.
With only a few microliters of blood, our biochip reader provides a reliable and fast diagnosis for a wide range of diseases.
Advantages of the new CAMPTON Biochip Reader System
Traditional diagnostic tests usually require laboratories and excessive equipment and highly trained personnel to deliver results in slow and time-consuming processes (e.g. 1-3 days to obtain results).
Portable diagnostic devices like the CAMPTON Reader 100 overcome these limitations: The fully automated platform performs sample extraction, preparation, (amplification*) and detection within the self-contained disposable laboratory in a 'cartridge', making it easy to perform with minimal equipment and training.
The CAMPTON Reader 100 delivers rapid test results within minutes, enabling cost and time efficient diagnostics. The consolidated test design allows testing for both serological and molecular biology assays, reducing the need for multiple test platforms. Unlike competitors who often use optics to capture test results, our newly developed CAMPTON technology uses electrical signals, making the CAMPTON Reader 100 technology more robust and therefore suitable for use in almost any climate and even in the most remote locations.
Product category: Immuno assay testing, Diagnostic rapid tests, Diagnostic tests for cancer, Other infectious immunology testing, DNA testing, Polymerase chain reaction (PCR), Other molecular diagnostics testing
CAMPTON IgG-Antibodytest (SARS-CoV2)
The detection of putative neutralizing antibodies by ELISA takes 1 to 3 hours. The CAMPTON Diagnostics Reader 100 and the COVID-19 IgG test reduce the test time to 13 minutes.
With the CAMPTON COVID-19 IgG antibody test, patient samples are examined for antibodies against the SARS-CoV-2 virus, which can lead to COVID-19. To prevent further and rapid spread of infectious COVID-19, it is necessary to identify infectious patients with and without symptoms as well as recovered patients.
With our COVID-19 IgG antibody test, physicians can quickly and efficiently determine if and how many antibodies a patient has developed and can be considered cured. The test provides a reliable result from only a few microliters of serum or whole blood according to WHO guidelines during 13 minutes at the point of care, i.e. in the immediate vicinity of the patient's sample collection. This eliminates a time-consuming logistics chain with storage and transport of the samples.
With the CAMPTON COVID-19 IgG antibody test, patient samples are examined for antibodies against the SARS-CoV-2 virus, which can lead to COVID-19. To prevent further and rapid spread of infectious COVID-19, it is necessary to identify infectious patients with and without symptoms as well as recovered patients.
With our COVID-19 IgG antibody test, physicians can quickly and efficiently determine if and how many antibodies a patient has developed and can be considered cured. The test provides a reliable result from only a few microliters of serum or whole blood according to WHO guidelines during 13 minutes at the point of care, i.e. in the immediate vicinity of the patient's sample collection. This eliminates a time-consuming logistics chain with storage and transport of the samples.
Product category: Immuno assay testing, Diagnostic rapid tests, Diagnostic tests for cancer, Microbiological diagnosis, virology, equipment and systems for, Other infectious immunology testing, DNA testing, Polymerase chain reaction (PCR), Other molecular diagnostics testing
CAMPTON RT-LAMP-Test (SARS-CoV2)
The diagnosis of infections using gold standard PCR tests takes 1 to 3 hours. With the CAMPTON Diagnostics Reader 100 and the COVID-19 RT-LAMP test, the test time should be reduced to 30 minutes.
The CAMPTON COVID-19 RT-LAMP Test is used to screen patient samples for the SARS-CoV-2 virus, which can lead to COVID-19. To prevent further and rapid spread of infectious COVID-19, it is necessary to identify infectious patients with and without symptoms.
With our RT-LAMP test for COVID-19, physicians can quickly and efficiently identify affected patients and immediately initiate the appropriate treatment. The test is designed to provide a reliable result in less than 30 minutes at the point of care, i.e. in the immediate vicinity of the patient's sample collection, using nucleic acid amplification according to WHO guidelines. This eliminates a time-consuming logistics chain with storage and transport of the samples.
The CAMPTON COVID-19 RT-LAMP Test is used to screen patient samples for the SARS-CoV-2 virus, which can lead to COVID-19. To prevent further and rapid spread of infectious COVID-19, it is necessary to identify infectious patients with and without symptoms.
With our RT-LAMP test for COVID-19, physicians can quickly and efficiently identify affected patients and immediately initiate the appropriate treatment. The test is designed to provide a reliable result in less than 30 minutes at the point of care, i.e. in the immediate vicinity of the patient's sample collection, using nucleic acid amplification according to WHO guidelines. This eliminates a time-consuming logistics chain with storage and transport of the samples.
Company news
Date
Topic
16 Nov 2020
CAMPTON Diagnostics presents fully automated point-of-care platform for fast test results
CAMPTON Reader 100 enables the detection of biomarkers e.g. for infections, cancer, autoimmune or other diseases from a whole blood sample within a few minutes
Serological and molecular biological tests for corona in preparation
Itzehoe, 16.11.2020 - At this year's MEDICA, CAMPTON Diagnostics will present the first generation of its CAMPTON Reader 100, a point-of-care system that will in future enable reliable statements to be made on the diagnosis of infections, cancer or other diseases within minutes from small quantities of whole blood. In addition, CAMPTON Diagnostics is developing an RT-LAMP-based as well as a serological test for CORONA for almost simultaneous measurement by the device.
The CAMPTON Reader carries out the test sequence and detection within the self-contained "disposable laboratory" in a cartridge. The technology is based on the so-called "electrical biochip technology". This system enables the detection of several biomarkers, e.g. for infections, cancer, autoimmune or other diseases, from a whole blood sample within a few minutes using an ELISA directly on a gold electrode array.
Faster diagnosis and therapy through diagnostics at the point of care
"Our system is portable, easy to operate and could therefore be very well suited for use regardless of location - later in a further generation of devices, e.g. also directly at the patient's home. Already during the waiting time at the doctor's, results can be determined for a faster treatment of possible diseases. In this way we are contributing to faster diagnostics and therapy as well as to an improvement in medical care", explains Jürgen Brink, CEO of CAMPTON Diagnostics.
In contrast to many competitor products, the newly developed CAMPTON technology uses electrical signals for analysis. For this reason, we believe that the CAMPTON technology is more robust and suitable for use in practically any climate (especially in emerging markets).
Automated test execution and semi-parallel protein and DNA analysis
The diagnostic device carries out the tests fully automatically in disposable microfluidic cartridges according to internal test protocols. The CAMPTON Reader 100 is designed to identify diseases with various biological substances. After a few minutes, the analysis results are shown on the display, e.g. as real values. The protocols are test-specific like the reagents and capture molecules on the corresponding biochip, while the device is always identical. Therefore the use of the CAMPTON biochip system is not limited to certain diseases.
It is possible to integrate almost any ELISA-based test into the biochip platform as long as disease-specific proteins are present in body fluids such as blood. It is also possible to perform DNA tests and protein ELISAs on a single hardware basis.
High miniaturisation potential for mobile use of the platform
The system based on electrical biochips is extremely miniaturisable. In the next generation of readers, it will consist only of very compact electronics and disposable cartridges with integrated pumps and ready-to-use reagents. "Our goal in developing the system was to create a universal technology platform for diagnostics, which above all should be highly miniaturisable and thus have all the prerequisites for mobility. Our platform also offers the possibility of simultaneous protein and DNA analysis," explains Lars Blohm, CTO of CAMPTON.
Serological and molecular biological bioassays for CORONA in development
CAMPTON Diagnostics is currently developing a serological and a molecular biological test for CORONA (SARS-CoV-2) for the biochip reader for almost simultaneous measurement. The aim is to use both methods to measure successively with different cartridges from a blood sample and a smear. The CORONA bioassays are expected to be available in 2021, when the pandemic hopefully loses strength and random point-of-care testing will become necessary.
Serological and molecular biological tests for corona in preparation
Itzehoe, 16.11.2020 - At this year's MEDICA, CAMPTON Diagnostics will present the first generation of its CAMPTON Reader 100, a point-of-care system that will in future enable reliable statements to be made on the diagnosis of infections, cancer or other diseases within minutes from small quantities of whole blood. In addition, CAMPTON Diagnostics is developing an RT-LAMP-based as well as a serological test for CORONA for almost simultaneous measurement by the device.
The CAMPTON Reader carries out the test sequence and detection within the self-contained "disposable laboratory" in a cartridge. The technology is based on the so-called "electrical biochip technology". This system enables the detection of several biomarkers, e.g. for infections, cancer, autoimmune or other diseases, from a whole blood sample within a few minutes using an ELISA directly on a gold electrode array.
Faster diagnosis and therapy through diagnostics at the point of care
"Our system is portable, easy to operate and could therefore be very well suited for use regardless of location - later in a further generation of devices, e.g. also directly at the patient's home. Already during the waiting time at the doctor's, results can be determined for a faster treatment of possible diseases. In this way we are contributing to faster diagnostics and therapy as well as to an improvement in medical care", explains Jürgen Brink, CEO of CAMPTON Diagnostics.
In contrast to many competitor products, the newly developed CAMPTON technology uses electrical signals for analysis. For this reason, we believe that the CAMPTON technology is more robust and suitable for use in practically any climate (especially in emerging markets).
Automated test execution and semi-parallel protein and DNA analysis
The diagnostic device carries out the tests fully automatically in disposable microfluidic cartridges according to internal test protocols. The CAMPTON Reader 100 is designed to identify diseases with various biological substances. After a few minutes, the analysis results are shown on the display, e.g. as real values. The protocols are test-specific like the reagents and capture molecules on the corresponding biochip, while the device is always identical. Therefore the use of the CAMPTON biochip system is not limited to certain diseases.
It is possible to integrate almost any ELISA-based test into the biochip platform as long as disease-specific proteins are present in body fluids such as blood. It is also possible to perform DNA tests and protein ELISAs on a single hardware basis.
High miniaturisation potential for mobile use of the platform
The system based on electrical biochips is extremely miniaturisable. In the next generation of readers, it will consist only of very compact electronics and disposable cartridges with integrated pumps and ready-to-use reagents. "Our goal in developing the system was to create a universal technology platform for diagnostics, which above all should be highly miniaturisable and thus have all the prerequisites for mobility. Our platform also offers the possibility of simultaneous protein and DNA analysis," explains Lars Blohm, CTO of CAMPTON.
Serological and molecular biological bioassays for CORONA in development
CAMPTON Diagnostics is currently developing a serological and a molecular biological test for CORONA (SARS-CoV-2) for the biochip reader for almost simultaneous measurement. The aim is to use both methods to measure successively with different cartridges from a blood sample and a smear. The CORONA bioassays are expected to be available in 2021, when the pandemic hopefully loses strength and random point-of-care testing will become necessary.
About us
Company portrait
CAMPTON Diagnostics GmbH was spun off from the Fraunhofer Institute for Silicon Technology (ISIT) in Itzehoe in 2016.
The company develops and markets complete measuring systems for point-of-care diagnostics, i.e. for on-site examinations of patients. CAMPTON Diagnostics combines biotechnological and engineering know-how under one roof.
The "Biochip Reader" device developed by CAMPTON uses silicon-based biochips from Fraunhofer ISIT. The ISIT manufactures these in the institute's own clean room.
Within a few minutes, the system, which is based on "electrical biochip technology", can make reliable statements about the indication of infections, cancer or other diseases from a drop of whole blood. The tests are particularly fast, highly sensitive and allow the simultaneous measurement of several parameters in one sample.
Disposable cartridges with integrated biochip are used for the measurements. The biochip works like a conventional ELISA test, but is electrically readable and thus enormously miniaturizable.
The company develops and markets complete measuring systems for point-of-care diagnostics, i.e. for on-site examinations of patients. CAMPTON Diagnostics combines biotechnological and engineering know-how under one roof.
The "Biochip Reader" device developed by CAMPTON uses silicon-based biochips from Fraunhofer ISIT. The ISIT manufactures these in the institute's own clean room.
Within a few minutes, the system, which is based on "electrical biochip technology", can make reliable statements about the indication of infections, cancer or other diseases from a drop of whole blood. The tests are particularly fast, highly sensitive and allow the simultaneous measurement of several parameters in one sample.
Disposable cartridges with integrated biochip are used for the measurements. The biochip works like a conventional ELISA test, but is electrically readable and thus enormously miniaturizable.
Company data
Number of employees
1-19
Foundation
2016
Area of business
Diagnostics